Senotherapeutics have been shown to reduce senescent cell burden in diet-induced obesity, to alleviate metabolic dysfunction, and to restore the capacity of preadipocytes to differentiate into functional insulin-responsive fat cells (88). This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.